Abstract: Devices, compositions, and methods for achieving non-surgical lung volume reduction (e.g., bronchoscopic lung volume reduction (BLVR)) are described. BLVR can be carried out by collapsing a region of the lung, adhering one portion of the collapsed region to another, and promoting fibrosis in or around the adherent tissue.

Abstract: The present invention relates to a method for administering a pharmaceutical preparation comprising at least one active substance to the olfactory region of a human. The method comprises administering a unit dose of the preparation by ejection from a nasal spray device (1) through a nostril of a human, the device and the pharmaceutical preparation being adapted so that the spray angle (3) is at the most 35°. The method is useful for the treatment of diseases affecting the olfactory organ, the brain and the central nervous system. The present invention also relates to a nasal spray device (1) comprising a pharmaceutical preparation. The pharmaceutical preparation preferably contains a viscosity enhancing agent and the pharmaceutical preparation preferably has a dynamic viscosity in the range of 5-300 cP.

Abstract: A device for the formation and delivery of a mixture, notably a surgical adhesive, consisting of a receptacle adapted for easy handling by the surgeon, and including the means of receiving two syringe barrels containing the constituents of the mixture, the means of simultaneously expelling the contents, the means of maintaining the contents of syringe containing the first constituent, at a predetermined temperature setting which is higher than body temperature, and a mixer simultaneously receiving the contents of the two syringes, and the mixer also being used for cooling.

Abstract: Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a cell surface of the vascular smooth muscle cell, coupled to a therapeutic agent dosage form that inhibits a cellular activity of the muscle cell. Methods are also provided for the direct and/or targeted delivery of therapeutic agents to vascular smooth muscle cells that cause a dilation and fixation of the vascular lumen by inhibiting smooth muscle cell contraction, thereby constituting a biological stent.

Abstract: A filling device for connecting a dispensing instrument having multiple fluid reservoirs to multiple containers is disclosed. More particularly, the present invention discloses a connecting device capable of coupling the individual reservoirs of a dispensing instrument to multiple fluid containers. The apparatus includes a body, a collar extending from the body, a plurality of tubes in fluid communication with a plurality of inlet ports formed in the body, and a hood adapted to simultaneously receive a plurality of containers therein. The containers are positioned within the hood to allow the plurality of tubes to simultaneously and separately draw fluid from the fluid containers and transferring the material into the individual reservoirs of the dispensing instrument.

Abstract: A composition useful as an embolic agent that selectively creates an embolic blockage in the lumen of a blood vessel, duct, fistula or other like body passageways by combining a monomer component and a second component wherein, said monomer component comprises of a alkyl cyanoacrylate monomer and at least one inhibitor agent; and said second component that functions as an opacificant agent and a polymerization retardant.

Abstract: Containers and methods for storing medical solutions are provided. More specifically, containers and methods for storing components that are to be admixed together to create a final solution, one of the components comprising a lipid. In an embodiment, a container including an interior defining at least two chambers. The first chamber includes a lipid containing liquid. The second chamber includes a liquid that does not include a lipid. The first and second chambers are separated by an openable seal.

Abstract: Containers and methods for storing medical solutions are provided. More specifically, containers and methods for storing components that are to be admixed together to create a final solution, one of the components comprising a lipid. In an embodiment, a container including an interior defining at least two chambers. The first chamber includes a lipid containing liquid. The second chamber includes a liquid that does not include a lipid. The first and second chambers are separated by an openable seal.

Abstract: A dispensing tube containing a selected material, such as bacterial cells or other additive, on the inside of the tube. The tube is wrapped and sealed in an outer watertight envelope until time for usage. At the time of usage the outer envelope is taken away and when the tubular device penetrates a solution container such as a beverage or an enteral solution, the selected material is added to the solution while the solution flows through the tube.

Abstract: A cassette is described including a housing, an inner reservoir located within the housing, a valve coupled to the inner reservoir and coupled to the housing, and a delivery conduit coupled to the inner reservoir and emerging from the delivery opening of the cassette. The cassette also includes a dispensing apparatus that defines a passage and has a first activating device that opens the valve of the cassette. The dispensing apparatus also has a second activating member capable of establishing fluid communication with a medicant container. A method of mixing a powdered drug and a liquid includes establishing fluid communication between the reservoir and the medicant container, dispensing at least a portion of the liquid into the medicant container, and transferring the mixed drug into the reservoir.

Abstract: In order to prevent conception and/or the spread of sexually transmitted diseases (STD's) one or more lectins capable of binding sperm and/or the pathogenic microorganisms responsible for STD's are administered to the vagina prior to sexual intercourse. The lectins immobilize the sperm to render them incapable of fertilization and also bind to the microorganisms to render them non-pathogenic or to the cells to prevent infection by the microorganisms. Lectins can also be administered to treat sexually transmitted vaginal infections. The invention also encompasses a device for to be placed in the vault of the vagina which comprises a ring which surrounds the cervix and a membrane spanning the central aperture of the ring to prevent the direct contact of ejaculate with the cervical tissues. The device is impregnated or coated with lectins and releases them into the vaginal environment over a period of time.

Abstract: In order to prevent conception and/or infection by sexually transmitted diseases (STDs) one or more lectins capable of binding sperm or agglutinable components of male ejaculate and/or the pathogenic microorganisms responsible for STDs or the carbohydrate moieties expressed on cell surfaces by which the microorganisms bind to the cells, are administered to the vagina prior to sexual intercourse. The lectins prevent conception by binding to the sperm or agglutinable components of male ejaculate to render the sperm incapable of fertilization. They also bind to the pathogenic microorganisms to render them non-pathogenic or to carbohydrates expressed on cell surfaces to prevent infection by the microorganisms or treat such infections. Lectins can also be administered to treat sexually transmitted vaginal infections. The lectins can also be applied to or contained within a condom.